Published January 27, 2024 | Version v1
Publication Open

Immunoinformatics approaches in developing a novel multi-epitope chimeric vaccine protective against Saprolegnia parasitica

  • 1. Kazi Nazrul University
  • 2. Maharshi Dayanand University
  • 3. Université Laval
  • 4. King Saud University
  • 5. Bahir Dar University
  • 6. Université Ibn Zohr

Description

Saprolegnia parasitica is responsible for devastating infections in fish and poses a tremendous threat to the global aquaculture industry. Presently, no safe and effective control measures are available, on the contrary, use of banned toxic compounds against the pathogen is affecting humans via biomagnification routes. This pioneering study aims to design an effective multi-epitope multi-target vaccine candidate against S. parasitica by targeting key proteins involved in the infection process. The proteins were analyzed and linear B-cell epitopes, MHC class I, and class II epitopes were predicted. Subsequently, highly antigenic epitopes were selected and fused to a highly immunogenic adjuvant, 50S ribosomal protein L7/L12, to design a multi-epitope chimeric vaccine construct. The structure of the vaccine was generated and validated for its stereochemical quality, physicochemical properties, antigenicity, allergenicity, and virulence traits. Molecular docking analyses demonstrated strong binding interactions between the vaccine and piscine immune receptors (TLR5, MHC I, MHC II). Molecular dynamics simulations and binding energy calculations of the complexes, further, reflected the stability and favorable interactions of the vaccine and predicted its cytosolic stability. Immune simulations predicted robust and consistent kinetics of the immune response elicited by the vaccine. The study posits the vaccine as a promising solution to combat saprolegniasis in the aquaculture industry.

⚠️ This is an automatic machine translation with an accuracy of 90-95%

Translated Description (Arabic)

الرثية الطفيلية مسؤولة عن الالتهابات المدمرة في الأسماك وتشكل تهديدًا هائلاً لصناعة الاستزراع المائي العالمية. في الوقت الحاضر، لا تتوفر تدابير مراقبة آمنة وفعالة، على العكس من ذلك، فإن استخدام المركبات السامة المحظورة ضد العامل الممرض يؤثر على البشر عبر طرق التضخم البيولوجي. تهدف هذه الدراسة الرائدة إلى تصميم لقاح فعال متعدد الأهداف ضد الطفيليات من خلال استهداف البروتينات الرئيسية المشاركة في عملية العدوى. تم تحليل البروتينات وتوقع وجود قمم لاصقة خطية للخلايا البائية، وقمم لاصقة MHC من الفئة الأولى، وقمم لاصقة من الفئة الثانية. في وقت لاحق، تم اختيار حواتم عالية المستضد ودمجها مع مادة مساعدة عالية المناعة، بروتين ريبوسومي 50S L7/L12، لتصميم بنية لقاح خيمري متعدد الحواتم. تم إنشاء هيكل اللقاح والتحقق من صحته لجودته الكيميائية الفراغية، وخصائصه الكيميائية الفيزيائية، وتولد المستضدات، والحساسية، وسمات الفوعة. أظهرت تحليلات الالتحام الجزيئي تفاعلات ربط قوية بين اللقاح ومستقبلات التجمع المناعي (TLR5، MHC I، MHC II). كما عكست محاكاة الديناميات الجزيئية وحسابات الطاقة الملزمة للمجمعات الاستقرار والتفاعلات المواتية للقاح وتنبأت باستقراره الخلوي. تنبأت المحاكاة المناعية بحركية قوية ومتسقة للاستجابة المناعية التي أثارها اللقاح. تطرح الدراسة اللقاح كحل واعد لمكافحة داء الرمد في صناعة الاستزراع المائي.

Translated Description (English)

Parasitic saprolegnia is responsible for devastating infections in fish and poses a tremendous threat to the global aquaculture industry. Presently, no safe and effective control measures are available, on the contrary, use of banned toxic compounds against the pathogen is affecting humans via biomagnification routes. This pioneering study aims to design an effective multi-epitope multi-target vaccine candidate against S. parasitica by targeting key proteins involved in the infection process. The proteins were analyzed and linear B-cell epitopes, MHC class I, and class II epitopes were predicted. Subsequently, highly antigenic epitopes were selected and fused to a highly immunogenic adjuvant, 50S ribosomal protein L7/L12, to design a multi-epitope chimeric vaccine construct. The structure of the vaccine was generated and validated for its stereochemical quality, physicochemical properties, antigenicity, allergenicity, and virulence traits. Molecular docking analyses demonstrated strong binding interactions between the vaccine and immune pool receptors (TLR5, MHC I, MHC II). Molecular dynamics simulations and binding energy calculations of the complexes, further, reflected the stability and favorable interactions of the vaccine and predicted its cytosolic stability. Immune simulations predicted robust and consistent kinetics of the immune response elicited by the vaccine. The study posits the vaccine as a promising solution to combat saprolegniasis in the aquaculture industry.

Translated Description (French)

Saprolegnia parasitica est responsable des infections dévastatrices dans les poissons et les poses d'un terrible danger pour l'industrie mondiale de l'aquaculture. Presently, no safe and effective control measures are available, on the contrary, use of banned toxic compounds against the pathogen is affecting humans via biomagnification routes. This pioneering study aims to design an effective multi-epitope multi-cible vaccines candidate against S. parasitica by targeting key proteins involved in the infection process. The proteins were analyzed and linear B-cell epitopes, MHC class I, and class II epitopes were predicted. Subsequently, highly antigenic epitopes were selected and fused to a highly immunogenic adjuvant, 50S ribosomal protein L7/L12, to design a multi-epitope chimeric vaccine construct. The structure of the vaccine was generated and validated for its stereochemical quality, physicochemical properties, antigenicity, allergenicity, and virulence traits. Molecular docking analyses demonstrated strong binding interactions between the vaccine and piscines immune receptors (TLR5, MHC I, MHC II). Molecular dynamics simulations and binding energy calculations of the complexes, further, reflected the stability and favorable interactions of the vaccine and predicted its cytosolic stability. Immune simulations predicted robust and consistent kinetics of the immune response elicited by the vaccine. The study posits the vaccine as a proming solution to combat saprolegniasis in the aquaculture industry.

Translated Description (Spanish)

Saprolegnia parasitica is responsible for devastating infections in fish and poses a tremendous threat to the global aquaculture industry. Presently, no safe and effective control measures are available, on the contrary, use of banned toxic compounds against the pathogen is affecting humans via biomagnification routes. This pioneering study aims to design an effective multi-epitope multi-target vaccine candidate against S. parasitica by targeting key proteins involved in the infection process. The proteins were analyzed and linear B-cell epitopes, MHC class I, and class II epitopes were predicted. Subsecuente, highly antigenic epitopes were selected and fused to a highly immunogenic adjuvant, 50S ribosomal protein L7/L12, to design a multi-epitope chimeric vaccine construct. The structure of the vaccine was generated and validated for its stereochemical quality, physicochemical properties, antigenicity, allergenicity, and virulence traits. Molecular docking analyses demonstrated strong binding interactions between the vaccine and piscine immune receptors (TLR5, MHC I, MHC II). Molecular dynamics simulations and binding energy calculations of the complexes, further, reflected the stability and favorable interactions of the vaccine and predicted its cytosolic stability. Immune simulations predicted robust and consistent kinetics of the immune response elicited by the vaccine. The study posits the vaccine as a promising solution to combat saprolegniasis in the aquaculture industry.

Files

s41598-024-52223-z.pdf.pdf

Files (5.0 MB)

⚠️ Please wait a few minutes before your translated files are ready ⚠️ Note: Some files might be protected thus translations might not work.
Name Size Download all
md5:f3086800b8aa96eb43d7216ceeab74ba
5.0 MB
Preview Download

Additional details

Additional titles

Translated title (Arabic)
نهج المعلوماتية المناعية في تطوير لقاح خيالي جديد متعدد الحواتم وقائي ضد الرمد الطفيلي
Translated title (English)
Immunoinformatics approaches in developing a novel multi-epitope chimeric vaccine protective against Parasitic Saprolegnia
Translated title (French)
Immunoinformatics approaches in developing a novel multi-epitope chimeric vaccines protective against Saprolegnia parasitica
Translated title (Spanish)
Immunoinformatics approaches in developing a novel multi-epitope quimeric vaccine protective against Saprolegnia parasitica

Identifiers

Other
https://openalex.org/W4391269831
DOI
10.1038/s41598-024-52223-z

GreSIS Basics Section

Is Global South Knowledge
Yes
Country
Morocco

References

  • https://openalex.org/W1031578623
  • https://openalex.org/W1602082788
  • https://openalex.org/W1869576842
  • https://openalex.org/W1983016612
  • https://openalex.org/W1989647405
  • https://openalex.org/W1992192767
  • https://openalex.org/W2015176909
  • https://openalex.org/W2017321063
  • https://openalex.org/W2020719323
  • https://openalex.org/W2024648909
  • https://openalex.org/W2025662227
  • https://openalex.org/W2030401841
  • https://openalex.org/W2074827833
  • https://openalex.org/W2075878132
  • https://openalex.org/W2089406088
  • https://openalex.org/W2101340968
  • https://openalex.org/W2102367710
  • https://openalex.org/W2110298304
  • https://openalex.org/W2115349230
  • https://openalex.org/W2116914853
  • https://openalex.org/W2118200955
  • https://openalex.org/W2118890972
  • https://openalex.org/W2120094728
  • https://openalex.org/W2120399005
  • https://openalex.org/W2124672930
  • https://openalex.org/W2147019716
  • https://openalex.org/W2152065574
  • https://openalex.org/W2159203645
  • https://openalex.org/W2168036974
  • https://openalex.org/W2171268876
  • https://openalex.org/W2271914738
  • https://openalex.org/W2343370142
  • https://openalex.org/W2433834875
  • https://openalex.org/W2487076382
  • https://openalex.org/W2568617656
  • https://openalex.org/W2572080171
  • https://openalex.org/W2620185010
  • https://openalex.org/W2740594895
  • https://openalex.org/W2783128639
  • https://openalex.org/W2787262788
  • https://openalex.org/W2807249455
  • https://openalex.org/W2888825838
  • https://openalex.org/W2894318891
  • https://openalex.org/W2898389621
  • https://openalex.org/W2922503279
  • https://openalex.org/W2936593880
  • https://openalex.org/W2990139883
  • https://openalex.org/W3000280551
  • https://openalex.org/W3022046133
  • https://openalex.org/W3033444236
  • https://openalex.org/W3037780053
  • https://openalex.org/W3092846859
  • https://openalex.org/W3105481944
  • https://openalex.org/W3155908830
  • https://openalex.org/W3199645614
  • https://openalex.org/W3202287440
  • https://openalex.org/W4239064538
  • https://openalex.org/W4294286537
  • https://openalex.org/W4298006291
  • https://openalex.org/W4298046671
  • https://openalex.org/W4302009161
  • https://openalex.org/W4319310648
  • https://openalex.org/W4320920124
  • https://openalex.org/W4386590258